Insmed stock tanked Thursday after its new lung drug, Brinsupri, missed elevated buy-side expectations, though beat sell-side views.

Insmed INSM reported a first-quarter 2026 loss of 76 cents per share, which was narrower than the Zacks Consensus Estimate of ...

Insmed's updated fair value estimate has shifted slightly, from US$214.32 to US$212.50 per share, putting fresh attention on how analysts are recalibrating their views. Recent reports around Brinsupri ...

We recently compiled a list of the Top 10 AI-Powered Biotech Stocks to Buy Right Now. Insmed Incorporated is one of the best biotech stocks. TheFly reported on April 16 that Guggenheim Securities ...

Insmed Inc (NASDAQ: INSM) was nothing short of a powerhouse last month, soaring 45%, while the S&P 500 index rose 3% in the same timeframe. What’s driving this surge? Insmed revealed that its Phase ...

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Global equity markets continued ...

As of January 14, 2026, the average one-year price target for Insmed is $217.87/share. The forecasts range from a low of $158.57 to a high of $253.05. The average price target represents an increase ...

William Blair initiated coverage on Insmed Incorporated (NASDAQ:INSM), citing that the clinical and commercial execution of its drugs can significantly increase Insmed's valuation. “While ...

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Mid Cap Growth Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the ...